Rhumbline Advisers Acquires 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Rhumbline Advisers boosted its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 24.0% during the 4th quarter, Holdings Channel reports. The firm owned 53,172 shares of the company’s stock after acquiring an additional 10,290 shares during the period. Rhumbline Advisers’ holdings in Cardiff Oncology were worth $231,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CRDF. HB Wealth Management LLC bought a new stake in shares of Cardiff Oncology during the 4th quarter worth $105,000. Barclays PLC raised its position in Cardiff Oncology by 291.9% in the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares during the period. XTX Topco Ltd raised its position in Cardiff Oncology by 44.3% in the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after acquiring an additional 36,947 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Cardiff Oncology by 11.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock valued at $324,000 after acquiring an additional 12,503 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in shares of Cardiff Oncology by 432.7% during the 3rd quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after acquiring an additional 151,613 shares during the period. Institutional investors own 16.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Piper Sandler lifted their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright raised their target price on Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of Cardiff Oncology stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the purchase, the director now owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.80% of the stock is currently owned by corporate insiders.

Cardiff Oncology Stock Down 0.5 %

Shares of NASDAQ:CRDF opened at $3.86 on Monday. The firm has a market capitalization of $197.38 million, a PE ratio of -4.11 and a beta of 1.73. The company has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $3.30. Cardiff Oncology, Inc. has a twelve month low of $2.01 and a twelve month high of $6.42.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.